| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
TRPV1; Natural flavone; anti-inflammatory, anti-tumor, anti-oxidant, neuroprotective, anti-fungal activities
Chrysin 6-C-glucoside 8-C-arabinoside targets multiple biological targets. It inhibits α-glucosidase, an enzyme that breaks down carbohydrates into glucose, thereby helping to control postprandial blood sugar levels. It also inhibits the release of calcitonin gene-related peptide (CGRP) and the activation of the TRPV1 channel, which are key mediators in migraine pathogenesis. |
|---|---|
| ln Vitro |
Twenty-six common peaks were assigned and identified from the fingerprints of different proportions DJS extracts. In vitro experimental results showed that DJS extracts inhibited inflammation and release of CGRP from trigeminal nerve cells. Five predicted active compounds, Chrysin 6-C-arabinoside 8-C-glucoside, Chrysin 6-C-glucoside 8-C-arabinoside, baicalin, Chrysin-7-O-Beta-D-glucoronide and Oroxylin A 7-O-glucuronide were sorted out according to spectrum-effect relationship analysis and molecular docking comprehensively. In vitro validation experiments showed that all the predicted compounds inhibited the CGRP releasing and the activation of TRPV1 channel. Baicalin, chrysin-7-O-β-D-glucuronide and Oroxylin A-7-glucoronide significantly inhibited the activation of TRPV1 channel.
Conclusion: Chrysin 6-C-arabinoside 8-C-glucoside, Chrysin 6-C-glucoside 8-C-arabinoside, baicalin, Chrysin-7-O-Beta-D-glucoronide and Oroxylin A 7-O-glucuronide which can inhibit the CGRP releasing and the activation of TRPV1 channel were screened as the anti-migraine active compounds by spectrum-effect relationship analysis and molecular docking[1].
In vitro, chrysin 6-C-glucoside 8-C-arabinoside demonstrates inhibitory activity against α-glucosidase, making it a potential agent for managing type 2 diabetes. It also inhibits CGRP release and TRPV1 channel activation, suggesting it may be useful for anti-migraine research. Its activities are being investigated in various research models. |
| ln Vivo |
In vivo, chrysin 6-C-glucoside 8-C-arabinoside is being studied for its potential to treat type 2 diabetes and migraine. Its ability to inhibit α-glucosidase could help control blood sugar levels. Its effects on CGRP and TRPV1 suggest it may have therapeutic potential for migraine.
|
| Enzyme Assay |
This study aimed to uncover the anti-migraine active compounds from DJS and preliminary predicted the pharmacological mechanism by evaluating the spectrum-effect relationship between high-performance liquid chromatography (HPLC) fingerprints and anti-migraine effects of Duijinsan (DJS) extract combined with molecular docking.
Materials and methods: HPLC and LC-MS were applied for chemical analyses of DJS extracts in different proportions. Inhibition of DJS extracts on trigeminal nerve cell releasing calcitonin gene related peptide (CGRP) experiment was performed. The active compounds were screened by spectrum-effect relationship analysis and confirmed by molecular docking and the activities of major predicted compounds were validated in vitro[1].
The inhibitory activity of chrysin 6-C-glucoside 8-C-arabinoside against α-glucosidase is assessed using in vitro enzyme assays. The enzyme is incubated with a substrate and varying concentrations of the compound, and the IC50 is calculated. Its effect on CGRP release and TRPV1 activation is assessed in cell-based assays. |
| Cell Assay |
The cellular activity of chrysin 6-C-glucoside 8-C-arabinoside is evaluated in cell lines relevant to its targets. Its effect on glucose uptake or CGRP release is measured. Its effect on TRPV1-mediated calcium influx can be assessed using calcium imaging.
|
| Animal Protocol |
In animal studies, chrysin 6-C-glucoside 8-C-arabinoside would be administered to animal models of diabetes or migraine to assess its efficacy. Its effect on blood glucose levels or pain responses would be measured.
|
| ADME/Pharmacokinetics |
Chrysin 6-C-glucoside 8-C-arabinoside is a flavonoid glycoside with a molecular weight of 548.5. It is soluble in DMSO. Its pharmacokinetic properties are characteristic of flavonoids and are influenced by its glycoside structure.
|
| Toxicity/Toxicokinetics |
Toxicology data for chrysin 6-C-glucoside 8-C-arabinoside is limited. As a naturally occurring flavonoid derivative, it is generally considered to have a low toxicity profile. However, formal toxicology studies have not been conducted.
|
| References | |
| Additional Infomation |
Reports indicate that Scutellaria baicalensis contains 6-C-glucoside and 8-C-arabinoside, and relevant data is available for reference.
Chrysin 6-C-glucoside 8-C-arabinoside (CAS: 185145-34-0) is a research compound with dual inhibitory activities against α-glucosidase and the CGRP/TRPV1 pathway. Its potential applications in type 2 diabetes and migraine research make it a compound of interest for drug discovery. |
| Molecular Formula |
C26H28O13
|
|---|---|
| Molecular Weight |
548.492729187012
|
| Exact Mass |
548.152
|
| CAS # |
185145-34-0
|
| PubChem CID |
21722007
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
39
|
| Complexity |
908
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C(=C3O)[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)O)[C@H]5[C@@H]([C@H]([C@H](CO5)O)O)O)O2
|
| InChi Key |
ZGVGUTOTMNVHSX-VYUBKLCTSA-N
|
| InChi Code |
InChI=1S/C26H28O13/c27-7-13-18(31)21(34)23(36)26(39-13)15-19(32)14-10(28)6-12(9-4-2-1-3-5-9)38-24(14)16(20(15)33)25-22(35)17(30)11(29)8-37-25/h1-6,11,13,17-18,21-23,25-27,29-36H,7-8H2/t11-,13+,17-,18+,21-,22+,23+,25-,26-/m0/s1
|
| Chemical Name |
5,7-dihydroxy-2-phenyl-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]chromen-4-one
|
| Synonyms |
Chrysin 6-C-glucoside 8-C-arabinoside; 185145-34-0; 5,7-Dihydroxy-2-phenyl-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-8-((2S,3R,4S,5S)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)-4H-chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8232 mL | 9.1159 mL | 18.2319 mL | |
| 5 mM | 0.3646 mL | 1.8232 mL | 3.6464 mL | |
| 10 mM | 0.1823 mL | 0.9116 mL | 1.8232 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
